Tag: CBT > FDA Congress

Top Stories

FDA Takes Hands-Off Approach to Medicare’s CBD Product Program

The U.S. Food and Drug Administration commissioner clarified the agency’s enforcement posture related to CBD product coverage under Medicare’s new plan.

April 2, 2026

CBD Industry

White House Schedules Meeting for FDA’s New CBD Compliance Enforcement Policy

The president’s Office of Information and Regulatory Affairs will review the proposed rule on April 1.

March 26, 2026

Cannabis Rescheduling

Typical Dispensary to Save $268K Annually Under Schedule III Reclassification

Cannabis retailers in higher-volume states, such as Maryland, would save an average of $805,000 annually per store if the Section 280E tax burden is removed.

December 23, 2025

Cannabis Rescheduling

When Polarization Replaces Governance: Cannabis Rescheduling and the Cost of Fear-Based Leadership (Opinion)

Much of the industry conversation to Trump’s executive order defaults to doom narratives that generate engagement but produce minimal legislative leverage.

December 22, 2025

Hemp

FDA, DEA May ‘Lack the Resources’ to Enforce New Federal Hemp Product Ban

Congressional researchers are skeptical about how the federal agencies will oversee a new law to prohibit intoxicating hemp products.

December 8, 2025

Cannabis Industry Research

The Man Behind DEA’s Federal Marijuana Scam

DEA Senior Policy Adviser Matthew Strait defied presidential mandates for medical research, MMJ International Holdings claims.

January 28, 2025

Cannabis Industry Research

Medical Marijuana Act Signed by Biden Would Hinder Research Under Rescheduling

The Medical Marijuana and Cannabidiol Research Expansion Act’s requirements would remain under Schedule III, a congressional researcher says.

September 20, 2024

Cannabis Rescheduling

3 GOP Senators Tell DEA Not to Reschedule Cannabis

Led by former presidential candidate Mitt Romney, the senators argue rescheduling would violate an international treaty in letter to DEA administrator.

March 27, 2024

Cannabis Rescheduling

DEA’s 5-Factor Test Makes Rescheduling Cannabis Impossible

After HHS used its own two-part test to determine the plant’s ‘currently accepted medical use,’ rescheduling opponents urge DEA to keep its five-part test.

March 19, 2024

Cannabis Rescheduling

US Congressman Urges DEA to Expedite Rescheduling Cannabis

Rep. Steve Cohen of Tennessee wrote a letter to Administrator Anne Milgram pushing to initiate the rulemaking process “quickly.”

January 5, 2024

Federal Cannabis Legalization

US Congressman Introduces Bill to Remove Cannabis From CSA, Allow Interstate Commerce, Provide 280E Relief

The legislation has bipartisan support, including from the co-chairs of the Congressional Cannabis Caucus.

December 8, 2023

Cannabis Industry Research

The Impacts of Cannabis Rescheduling: Panelists Weigh In During International Cannabis Bar Association Webinar

Industry legal experts Khurshid Khoja, Amber Littlejohn and Shane Pennington shared insight into what rescheduling could mean for taxes, research and federal enforcement.

September 12, 2023